



Citi European Healthcare Conference

London | June 22, 2016



**FRESENIUS
MEDICAL CARE**




CREATING A FUTURE
WORTH LIVING

Fresenius Medical Care today

Every **0.7** seconds we **provide**
a **dialysis treatment**
somewhere on the globe



37
production sites



120,000,000
sold dialyzers



3,418
clinics



294,381
patients



44,596,446
dialysis treatments



104,033
employees



AGENDA



Market dynamics

1

Business update: Q1 2016


2

Financials & outlook

3





Expected global dialysis patient growth

- ▶ Expected patient growth of around 6% p.a.
- ▶ Driven by age, lifestyle and higher life expectancy



¹ Internal estimates

Dialysis services worldwide: Patients treated¹



**USD
~73bn
Market**


**We lead in every major market,
treating > 290,000 patients worldwide**

¹ as of December 31, 2015, based on company statements and own estimates.

Market position by major product groups 2015


	Position 1
Dialyzers	FMC
Dialysis machines	FMC
Hemodialysis concentrates	FMC
Bloodlines	FMC
Peritoneal dialysis products	Baxter

Dialyzers




■ FME
■ Competitors

Dialysis machines



Sold around 120 million dialyzers in 2015

Global presence: products & services



AGENDA



Market dynamics

1

Business update: Q1 2016

2

Financials & outlook


3

Strong start to the year

Q1 2016 Highlights

- ▶ Strong growth in group revenue and net income
- ▶ Excellent development in North American business
- ▶ EMEA, Asia Pacific and Latin America impacted by foreign currency headwinds
- ▶ Care Coordination with good organic growth
- ▶ First quarter performance in line to achieve full year guidance

Q1 2016 Performance (US\$ million)



Diagrams: different scales applied

Solid organic growth in all regions

North America


US\$ million

Revenue	3,044	+10%
Organic growth		+7%

EMEA, Asia-Pacific, Latin America

US\$ million

Revenue	1,158	+7% ^{cc}
Organic growth		+7%



1	North America	72%
2	EMEA	15%
3	Asia-Pacific	9%
4	Latin America	4%

EMEA

Revenue	631	+5% ^{cc}
Organic growth		+4%

Asia-Pacific

Revenue	374	+10% ^{cc}
Organic growth		+11%

Latin America

Revenue	153	+5% ^{cc}
Organic growth		+12%

cc = constant currency, corporate revenue = \$3m

Taking care of patients through global footprint



► Providing care to over **294,000 patients (+2%)**:

North America ~ 183,000
 EMEA ~ 55,000
 Latin America ~ 29,000
 Asia-Pacific ~ 27,000

	Clinics as of Mar 31, 2016	De novo Q1 2016	Acquired Q1 2016
Total	3,432	+22	+6
Growth year on year	+1%		
North America	2,224	+10	+6
Growth year on year	+2%		
EMEA, Latin America, Asia-Pacific	1,208	+12	-
Growth year on year	-		

Quality outcomes remain stable


% of patients	North America		EMEA		Latin America ¹		Asia-Pacific ¹	
	Q4 2015	Q1 2016	Q4 2015	Q1 2016	Q4 2015	Q1 2016	Q4 2015	Q1 2016
Kt/V ≥ 1.2	98	98	96	96	92	92	97	97
No catheter (>90 days)	84	85	82	82	83	82	91	91
Hemoglobin = 10 – 12 g/dl	72	72	77	78	52	52	60	58
Hemoglobin = 10 – 13 g/dl (International)	78	77	77	77	69	68	68	66
Albumin ≥ 3.5 g/dl	81	82	92	91	90	90	89	89
Phosphate ≤ 5.5 mg/dl	64	64	79	78	75	75	72	70
Calcium 8.4 – 10.2 mg/dl	84	84	77	74	75	76	75	74
Hospitalization days, per patient	10.0	10.0	9.4	9.4	3.5	3.5	4.2	4.3

¹ Outcome data in these regions might be more volatile over time as clinic data will be added

Health Care revenue continues to grow

	Q1 2016 US\$ million	Q1 2015 US\$ million	Growth in %	Growth in %cc	Organic growth in %	Same market growth in %
North America	2,832	2,571	10	10	8	4
of which Care Coordination	522	434	20	20	17	-
EMEA, Asia-Pacific, Latin America	582	611	(5)	6	7	4
Total Health Care	3,414	3,182	7	9	7	4

- ▶ 5% increase in dialysis treatments
- ▶ Higher revenue supported by favorable payer development
- ▶ Care Coordination with good organic growth




cc = constant currency

Dialysis Products show good demand

	Q1 2016 US\$ million	Q1 2015 US\$ million	Growth in %	Growth in %cc
North America	212	200	6	6
EMEA, Asia-Pacific, Latin America	576	569	1	8
Corporate	3	9	(63)	(62)
Total Dialysis Products	791	778	2	6

- ▶ Increased sales of dialyzers, machines and bloodlines
- ▶ Solid growth despite strong comparable first half 2015
- ▶ Foreign currency headwinds outside North America
- ▶ Global PD growth at 4% yoy (cc); North American PD growth at 15% yoy



PD = Peritoneal Dialysis, yoy = year-over-year, cc = constant currency

AGENDA



Market dynamics

1

Business update: Q1 2016

2

Financials & outlook



3

Profit grows faster than top line

	Q1 2016 in \$ million	Q1 2015 in \$ million	Growth in %
Net revenue	4,205	3,960	6
Operating income (EBIT)	540	504	7
<i>EBIT-margin in %</i>	12.8	12.7	(10bp)
Net interest expense	105	102	3
Income before taxes	435	402	8
Income tax expense	138	138	-
<i>Tax rate in %</i>	31.8	34.4	(250bp)
Non-controlling interest	69	54	25
Net income	228	210	9

- ▶ Revenue increased by 9% constant-currency, in line with full-year guidance
- ▶ Lower income tax expense due to increased noncontrolling interest in the US and lower tax rates in certain tax jurisdictions
- ▶ Net income supported by lower cost for healthcare supplies and savings from Global Efficiency Program

North America again with strong margin increase





in US\$ million

■ EBIT

○ EBIT-margin

Diagrams: different scales applied




Cash flow development and credit profile

Days sales outstanding (DSO) at 74 days worldwide.

	Q1 2016 in \$ million	Q1 2015 in \$ million
Operating cash flow	180	447
in % of revenue	4.3	11.3
Capital expenditures, net	(246)	(197)
Free cash flow	(66)	250
Free cash flow, after acquisitions and investments	(157)	239

Total debt/EBITDA-ratio




Current ratings

	S&P	Moody's	Fitch
Company	BBB-	Ba1	BB+
Outlook	stable	stable	stable

A reconciliation to the most directly comparable U.S. GAAP financial measures is provided in the attachments.

Outlook 2016 confirmed



- ▶ 2016 net income growth outlook is based on current exchange rates
- ▶ Savings from the Global Efficiency Program are included
- ▶ Acquisitions 2015/2016 are not included
- ▶ Net income growth based on US\$ 1,057 million in 2015

2020 growth strategy

**Opening up
new business
areas**

**Growing in our
core business**




**Enhancing
products and
treatments**

**Increasing
flexibility and
efficiency**

Long-term goals up to 2020

Revenue
in \$ billion



- ▶ We expect an average increase in net income in the high single-digit percentage range for the same period.
- ▶ We will continue to grow our dialysis services and products business.
- ▶ We plan to further expand our Care Coordination activities.

20 YEARS

CREATING A FUTURE
WORTH LIVING

Attachment 1

Reconciliation of non-US-GAAP financial measures to the most comparable US-GAAP measure

US\$ million

Debt	FY 2014 ¹⁾	FY 2015	Q1 2016
Short term borrowings	133	109	349
+ Short term borrowing from related parties	5	19	64
+ Current portion of long-term debt and capital lease obligations	314	664	678
+ Long-term debt and capital lease obligations less current portion	9,014	7,854	7,848
TOTAL debt	9,466	8,646	8,939

EBITDA	FY 2014 ²⁾	FY 2015 ²⁾	Q1 2016
Last twelve month operating income (EBIT)	2,347	2,327	2,363
+ Last twelve month depreciation and amortization	716	717	723
+ Non-cash charges	57	83	84
EBITDA (annualized)	3,120	3,127	3,170
Total Debt ¹⁾ / EBITDA	3.0	2.8	2.8

1) Reclassification of debt issuance costs from current / non-current assets to long-term liabilities

2) EBITDA: including largest acquisitions

Attachment 2

Reconciliation of non-US-GAAP financial measures to the most comparable US-GAAP measure


US\$ million

Cash Flow	Q1 2015	Q1 2016
Acquisitions, investments and net purchases of intangible assets	(22)	(91)
+ Proceeds from divestitures	11	-
= Acquisitions and investments, net of divestitures	(11)	(91)

Capital expenditures, net	Q1 2015	Q1 2016
Purchase of property, plant and equipment	(201)	(250)
- Proceeds from sale of property, plant & equipment	4	4
= Capital expenditure, net	(197)	(246)

Day sales outstanding (DSO)

in days



- ▶ The DSO increase in the North America Segment is largely due to a delay in invoicing within the quarter.

Patients, treatments, clinics

	Clinics as of Mar. 31, 2016	Patients as of Mar. 31, 2016	Treatments Q1 2016, in million
North America	2,224	182,808	7.1
Growth in %	2	3	6
EMEA	658	55,197	2.1
Asia-Pacific	323	26,713	1.0
Latin America	227	29,325	1.2
Total	3,432	294,043	11.3
Growth in %	1	2	5

Exchange rates

		Q1 2015	FY 2015	Q1 2016
€:\$	Period end	1.0759	1.0887	1.1385
	Average	1.1261	1.1095	1.1020
\$:CNY	Period end	6.2004	6.4855	6.4571
	Average	6.2367	6.2851	6.5427
\$:RUB	Period end	58.0351	74.1009	67.0225
	Average	63.0147	61.3538	74.8191
\$:ARS	Period end	8.8095	12.9825	14.6423
	Average	8.6890	9.2570	14.4491

U.S. dialysis days per quarter

	Q1	Q2	Q3	Q4	Full year
2014	76	78	79	80	313
2015	76	78	79	79	312
2016	78	78	79	79	314
2017	77	78	79	78	312

Safe harbor statement: This presentation includes certain forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. The Company has based these forward-looking statements on its views with respect to future events and financial performance. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic competitive conditions, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward-looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) reports filed with the Securities and Exchange Commission (SEC) and the German Exchange Commission (Deutsche Börse).

Forward-looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward-looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA independent of being the reported or the adjusted number. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in US-\$ if not mentioned otherwise.

Constant currency: Changes in revenue include the impact of changes in foreign currency exchange rates. We use the non-GAAP financial measure “at constant exchange rates” in our filings to show changes in our revenue without giving effect to period-to-period currency fluctuations. Under U.S. GAAP, revenues received in local (non-U.S. dollar) currency are translated into U.S. dollars at the average exchange rate for the period presented. When we use the term “constant currency,” it means that we have translated local currency revenues for the current reporting period into U.S. dollars using the same average foreign currency exchange rates for the conversion of revenues into U.S. dollars that we used to translate local currency revenues for the comparable reporting period of the prior year. We then calculate the change, as a percentage, of the current period revenues using the prior period exchange rates versus the prior period revenues. This resulting percentage is a non-GAAP measure referring to a change as a percentage “at constant exchange rates.”

We believe that revenue growth is a key indication of how a company is progressing from period to period and that the non-GAAP financial measure constant currency is useful to investors, lenders, and other creditors because such information enables them to gauge the impact of currency fluctuations on its revenue from period to period. However, we also believe that data on constant currency period-over-period changes have limitations, particularly as the currency effects that are eliminated could constitute a significant element of our revenue and could significantly impact our performance. We therefore limit our use of constant currency period-over-period changes to a measure for the impact of currency fluctuations on the translation of local currency revenue into U.S. dollars. We do not evaluate our results and performance without considering both constant currency period-over-period changes in non-U.S. GAAP revenue on the one hand and changes in revenue prepared in accordance with U.S. GAAP on the other. We caution the readers of this report to follow a similar approach by considering data on constant currency period-over-period changes only in addition to, and not as a substitute for or superior to, changes in revenue prepared in accordance with U.S. GAAP. We present the fluctuation derived from U.S. GAAP revenue next to the fluctuation derived from non-GAAP revenue. Because the reconciliation is inherent in the disclosure, we believe that a separate reconciliation would not provide any additional benefit.

Financial calendar *

Aug 2, 2016	Report on 2 nd quarter 2016
Oct 27, 2016	Report on 3 rd quarter 2016
June 22, 2016	Citi European Healthcare Conference, London
June 23, 2016	J.P. Morgan European Healthcare Conference, London
Sep 7, 2016	Goldman Sachs Medtech & Healthcare Conference, London

* Please note that dates and/or participation might be subject to change

Contacts

FME Investor Relations
Else-Kröner-Str. 1
61352 Bad Homburg v.d.H.
Germany

Ticker: FME or FMS (NYSE)
WKN: 578 580
ISIN: DE00057858002

▶ **Oliver Maier**

Head of Investor Relations and
Corporate Communications
Tel: +49-(0) 6172-609-2601
Email: oliver.maier@fmc-ag.com

▶ **Robert Adolph**

Director Investor Relations
Tel.: +49-(0) 6172-609-2477
Email: robert.adolph@fmc-ag.com

▶ **Juliane Beckmann**

Senior Manager Investor Relations
Tel.: +49-(0) 6172-609-5216
Email: juliane.beckmann@fmc-ag.com

▶ **Terry Morris**

VP Investor Relations North America
Tel: +1- 800-948-2538
Email: terry.morris@fmc-na.com





Citi European Healthcare Conference

London | June 22, 2016



**FRESENIUS
MEDICAL CARE**



CREATING A FUTURE
WORTH LIVING